Newsletter | September 21, 2021

09.21.21 -- Augmenting Human Intelligence In Drug Discovery With AI

Industry Insights
Align Your CMC Strategy With Clinical Path Requirements And Timeline

Manufacturers must understand the challenges associated with creating a CMC strategy in today’s crowded and diverse market and the expertise and resources needed to successfully execute it.

For mAbs, A Small Biotech Recognizes The Value In Lonza’s Expertise And Track Record

William B. Jones, senior vice president of pharmaceutical development at Corvus Pharmaceuticals, discusses his company’s selection of CDMO for its CPI-006 antibody program, which is currently under development as an oncology drug and investigation as a therapeutic for immune disorders and infectious diseases.

Development And Qualification Of A Complex Potency ELISA

Many new therapies are targeting the PD-1 pathway to boost the immune response to cancer cells. Current assays used to measure the activity of anti-PD-1 or anti-PD-L1 antibodies can be highly variable due to their reliance on primary cells and complex assay protocols. One method to demonstrate the activity of anti PD-1 molecules using a functionally relevant but less variable method is using a potency ELISA.

How Buffer pH And NaCl Affect Size Exclusion Chromatography

Using a design of experiments approach, this study describes the effect of buffer pH and NaCl concentration on proteins purified by size exclusion chromatography.

Digital Lab Documentation - Improve Collaboration, Productivity, & Reduce Costs

By implementing a digital lab solution, you can bridge the innovation and productivity gaps in research, development, manufacturing and quality, and enable successful technology transfer across new product development and production operations.

Most Popular News
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.